Rheumatology

Your Article Summary

See Latest Articles

New selective estrogen and androgen receptor modulators
Current Opinion in Rheumatology, 06/12/09

Clarke BL et al. - Lasofoxifene and arzoxifene are two newer SERMs that have recently been demonstrated to improve bone mineral density and lower serum cholesterol values compared with older SERMs in smaller clinical trials. SARMs are a newer category of drug still being investigated mostly at the basic and preclinical level, with fewer clinical trials available for review. SARMs are currently being investigated mostly for use in prostate cancer at different stages but hold promise for multiple other applications.

Related Articles

See all related articles

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Therapeutics and Clinical Risk Management, 10/16/09    Relevance Score: 91%

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

Regional migratory osteoporosis: case report of a patient with neuropathic pain
Rheumatology International, 12/20/09

Epidemiology of hip fracture in Tucuman, Argentina
Osteoporosis International, 12/19/09

Lateral back pain identifies prevalent vertebral fractures in post-menopausal women: Cross-sectional analysis of a primary care-based cohort
Rheumatology, 12/18/09

 See all of Bone Metabolism

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Malignancy-associated multicentric reticulohistiocytosis
Rheumatology International, 12/20/09

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
Rheumatology, 12/18/09

Nicotine-patch therapy on mucocutaneous lesions of Behcet's disease: A case series
Rheumatology, 12/18/09

 See all of Clinical Pharmacology